Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials

Aim To assess the lipid‐lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with hypercholesterolaemia and prediabetes at baseline vs people with normoglycaemia at baseline in a pooled analysis of 10 ODYSSEY phase III trials. Metho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetic medicine 2018-01, Vol.35 (1), p.121-130
Hauptverfasser: Leiter, L. A., Müller‐Wieland, D., Baccara‐Dinet, M. T., Letierce, A., Samuel, R., Cariou, B.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents - therapeutic use
Blood glucose
Blood Glucose - metabolism
Case-Control Studies
Cholesterol
Cholesterol, LDL - metabolism
Clinical trials
Clinical Trials, Phase III as Topic
Diabetes
Diabetes mellitus
Double-Blind Method
Fasting
Female
Glucose
Glycated Hemoglobin - metabolism
Homeostasis
Humans
Hypercholesterolemia - complications
Hypercholesterolemia - drug therapy
Hypercholesterolemia - metabolism
Kexin
Laboratory testing
Low density lipoprotein
Male
Middle Aged
Monoclonal antibodies
Motivation
Prediabetic State - complications
Prediabetic State - metabolism
Proprotein convertases
Randomized Controlled Trials as Topic
Research: Treatment
Safety
Statins
Subtilisin
Treatment Outcome
Triglycerides
Triglycerides - metabolism
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim To assess the lipid‐lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with hypercholesterolaemia and prediabetes at baseline vs people with normoglycaemia at baseline in a pooled analysis of 10 ODYSSEY phase III trials. Methods People classified as having prediabetes had baseline HbA1c ≥39 mmol/mol (5.7%) and
ISSN:0742-3071
1464-5491
DOI:10.1111/dme.13450